21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be essential for a preventative HIV-1 vaccine, but this has not yet been achieved by immunization. In contrast some HIV-1-infected individuals naturally mount bNAb responses during chronic infection, suggesting that years of maturation are required for breadth 1- 6 . Recent studies have shown that viral diversification precedes the emergence of bNAbs but the significance of this observation is unknown 7, 8 . Here, we delineate the key viral events that drove neutralization breadth within the CAP256-VRC26 family of 33 monoclonal antibodies (mAbs) isolated from a superinfected individual. First, we identified minority viral variants that were distinct from both transmitted/founder (T/F) viruses and efficiently engaged the bNAb precursor, termed bNAb-initiating envelopes. Second, deep sequencing revealed a pool of diverse epitope variants (immunotypes) that were preferentially neutralized by broader members of the antibody lineage. In contrast, a “dead-end” antibody sublineage unable to neutralize these immunotypes showed limited evolution and failed to develop breadth. Thus, early viral escape at key antibody-virus contact sites selects for sublineages that can tolerate these changes, providing a new mechanism for the generation of neutralization breadth within a developing antibody lineage.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences

          Increased reliance on computational approaches in the life sciences has revealed grave concerns about how accessible and reproducible computation-reliant results truly are. Galaxy http://usegalaxy.org, an open web-based platform for genomic research, addresses these problems. Galaxy automatically tracks and manages data provenance and provides support for capturing the context and intent of computational methods. Galaxy Pages are interactive, web-based documents that provide users with a medium to communicate a complete computational analysis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Positional effect of single bulge nucleotide on PNA(peptide nucleic acid)/DNA hybrid stability

            We report positional effect of bulge nucleotide on PNA/DNA hybrid stability. CD spectra showed that PNA/DNA hybrids required at least seven base pairings at a stem region to form a bulged structure. On the other hand, DNA/DNA could form bulged structure when there are only four base pairings adjacent to the bulge nucleotide. We discuss why PNA requests such a many base pairings to form bulged structure from a nearest neighbor standpoint.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Rational HIV immunogen design to target specific germline B cell receptors.

              Vaccine development to induce broadly neutralizing antibodies (bNAbs) against HIV-1 is a global health priority. Potent VRC01-class bNAbs against the CD4 binding site of HIV gp120 have been isolated from HIV-1-infected individuals; however, such bNAbs have not been induced by vaccination. Wild-type gp120 proteins lack detectable affinity for predicted germline precursors of VRC01-class bNAbs, making them poor immunogens to prime a VRC01-class response. We employed computation-guided, in vitro screening to engineer a germline-targeting gp120 outer domain immunogen that binds to multiple VRC01-class bNAbs and germline precursors, and elucidated germline binding crystallographically. When multimerized on nanoparticles, this immunogen (eOD-GT6) activates germline and mature VRC01-class B cells. Thus, eOD-GT6 nanoparticles have promise as a vaccine prime. In principle, germline-targeting strategies could be applied to other epitopes and pathogens.
                Bookmark

                Author and article information

                Journal
                9502015
                8791
                Nat Med
                Nat. Med.
                Nature medicine
                1078-8956
                1546-170X
                4 September 2015
                12 October 2015
                November 2015
                01 May 2016
                : 21
                : 11
                : 1332-1336
                Affiliations
                [1 ]Centre for HIV and STIs, National Institute for Communicable Diseases (NICD) of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
                [2 ]Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
                [3 ]Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
                [4 ]Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
                [5 ]Department of Biochemistry and Systems Biology, Columbia University, New York, New York, USA
                [6 ]Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu Natal, Durban, South Africa
                [7 ]National Health Laboratory Services, Johannesburg, South Africa
                Author notes
                [* ] Corresponding author: Penny L. Moore, pennym@ 123456nicd.ac.za

                AUTHOR CONTRIBUTIONS

                J.N.B., L.M. and P.L.M. designed the study, analysed data and wrote the manuscript. C.A. and C.W. designed and performed viral next-generation sequencing and analysis and edited the manuscript. N.A.D-R led the isolation of CAP256 mAbs. J.N.B. and O.K. performed neutralization experiments. C.A.S. and L.S. generated and analysed antibody NGS data. J.N.B. and T.K. expressed and purified monoclonal antibodies. J.N.B. and D.K. generated single-genome sequences and viral envelope clones. G.B. developed computational tools to analyse NGS data, and assisted in the NGS analysis. J.G. assessed CAP256-VRC26 UCA neutralization of heterologous viruses. N.J.G. and the CAPRISA Study Team managed the CAPRISA cohort and contributed samples and data for CAP256. S.S.A.K., C.W. and L.M. established and led the CAPRISA cohort. C.W., N.A.D-R, L.S, P.D.K, and J.R.M contributed to data analysis and edited the manuscript.

                Article
                EMS64963
                10.1038/nm.3963
                4637988
                26457756
                2534baf7-0ae7-43cd-9885-3c80a777d425

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Medicine
                Medicine

                Comments

                Comment on this article